Another CGRP-antibody Drug in Development

As recently discussed, CGRP plays a role in migraine, and CGRP antagonist drugs have been developed, but are not yet available for use. We discussed a new strategy to use an injectable antibody to CGRP.

Three posters presented at the International Headache Congress in Boston june 27 - 30, 2013, regarding a CGRP antibody product known as LBR-101. LBR-101 is a humanized monoclonal antibody that blocks the CGRP binding to its receptor. Labrys Biologics is developing LBR-101 for the treatment of chronic migraine.

The data presented at IHC 2013 indicate that LBR-101 has a long half-life, which should enable monthly dosing. Treatment related adverse events in the Phase I trial were mild, transient, and resolved spontaneously.

The potential for another treatment for chronic migraine is exciting.